In recent years, the natural course of HIV infection has as primary diagnoses among HIV-positive patients prescribed antiretroviral drugs during a 3-year period prior to and since changed dramatically [1] . Before 1995 the incidence of AIDS and AIDS-defining illnesses increased or remained static [2, the introduction of newer antiretroviral agents, from 1 January 1994 through 31 December 1996. The second objective of this 3], but since then stabilization in the incidence of AIDS-related opportunistic infections has been followed by a reduction in study was to determine whether there was a change in the spectrum or relative incidence of AIDS-defining illnesses durthe rate of new AIDS cases in the United States [1, 4, 5] . Progress in the management and prevention of the complicaing this period. tions of HIV disease had considerable impact on the clinical manifestations of AIDS in the era prior to the advent of highly Methods active antiretroviral therapy [6 -9] . However, it is unclear how the clinical course of HIV infection will evolve in patients Since 1986 , antiretroviral agents in the province of British receiving highly active antiretroviral therapy, particularly given Columbia, Canada, have been distributed at no cost to eligible the possibility that clinically significant immune reconstitution HIV-infected individuals through the HIV/AIDS Drug Treatwill be induced by such therapy [10 -16] .
ment Program, centrally administered through the British Columbia Center for Excellence in HIV/AIDS [17] . For physiSee editorial response by Miller and Goetz cians to prescribe antiretroviral drugs, they must complete a on pages 1386 -7.
participant enrollment form that acts as the drug prescription. This permits tracking of enrolled participants, determination of The purpose of this study was to assess the evolution in the the timing of development of AIDS, and identification of index incidence of AIDS-defining opportunistic infections and tumors AIDS diagnoses. In this way, manifestations of complications of HIV disease in individuals in British Columbia who are prescribed antiretroviral agents can be ascertained. From 1986 to 1997, a total of 3,968 HIV-positive British period on a continuous basis with use of physician reports and antiretroviral therapy. The median age of these 344 participants at the time of diagnosis of primary AIDS was 38 years (interthrough record linkages with the British Columbia provincial AIDS registry and Division of Vital Statistics.
quartile range, 34 -44 years). The median age at diagnosis of AIDS did not differ significantly between the 3 study years Rates were expressed as the number of primary AIDS diagnoses among those previously treated with antiretroviral drugs (P Å .908). The median value for the last CD4 / cell counts obtained within 12 months prior to the AIDS diagnosis was per 1,000 AIDS-free participants receiving antiretrovirals in a 6-month period. All rates were calculated on a 6-month basis 0.070 1 10 9 /L (interquartile range, 0.030 -0.130 1 10 9 /L). The median value did not differ significantly during the study period over a 3-year period, from 1 January 1994 through 31 December 1996. Patients with a first AIDS-defining illness were ex-(0.080 1 10 9 /L in 1994 vs. 0.060 1 10 9 /L in 1996; P Å .377 , and transfusion of other blood products in 11 (3.2%). Over the study period there was an increase in the tion, cytomegalovirus infection, dementia and other AIDSdefining neurological illnesses, and wasting syndrome), and the diagnosis of AIDS among injection drug users (10% in 1994 vs. 11% in 1996; P Å .894) and a decrease among homosexual rates of decline for each were calculated and compared. The relative proportion of different AIDS-defining illnesses was and bisexual men (81% in 1994 vs. 66% in 1996; P Å .023).
There was no substantial change in the AIDS case rate among compared for 1995 and 1996, relative to the baseline in 1994.
For further analysis, PCP, candidal infection, infection with patients who acquired disease through heterosexual transmission (8.97% in 1994 vs. 7.69% in 1996; P Å .761). The distribuMycobacterium tuberculosis, and herpes simplex virus infection were grouped and analyzed separately from other AIDStion of patients with varying levels of immunodeficiency, as reflected by CD4 / cell count, did not change through the period defining illnesses. This group of HIV-related complications is amenable to therapy, and if treated successfully, these compliof study (P Å .133; figure 1 ). During the study period, the incidence rates of primary AIDS cations do not contribute to limitation of life expectancy. In contrast, other AIDS-defining illnesses such as toxoplasmosis, diseases peaked in the first months of 1994 and reached their lowest values in the last 6 months of 1996. There were 80 MAC infection, progressive multifocal leukoencephalopathy, and lymphoma more often cannot be treated successfully and primary AIDS cases diagnosed per 1,000 antiretroviral-treated participants in the first 6 months of 1994. This number dropped often limit survival. The former group has been designated amenable, while all others were considered nonamenable [19, to 22 per 1,000 in the last 6 months of 1996. The overall number of primary AIDS cases decreased at a rate of 18 cases 20]. Analyzing these groups of diagnoses separately was important to determine if changes in the incidence of AIDSdefining illnesses and spectrum of disease were associated with changes in the extent to which the terminal stage of HIV infection (AIDS) was amenable to therapy during the study period.
Statistical Analysis
Categorical variables and ordinal and skewed continuous variables were compared with the Mantel-Haenszel test and Wilcoxon's rank-sum test, respectively. Fisher's exact test was used for 2 1 2 contingency tables in which any of the expected cell frequencies was õ5. Linear regression analysis was used to assess the rate of change in AIDS cases diagnosed over time. All reported P values are two-sided, and P õ .05 was considered statistically significant. 11-10-98 21:47:45 cida UC: CID per 1,000 every 6 months from 1994 to 1996 (P õ .001). The overall rate of decrease was related primarily to the sharp decline during the last 2 years (1995 and 1996). The primary AIDS diagnoses in this population treated with antiretroviral drugs decreased at a rate of 24 cases per 1,000 participants every 6 months during this 2-year period (P Å .004). Figure 2 represents the decline in AIDS incidence among participants receiving antiretroviral therapy before diagnosis, by major diagnosis category. The rate of decline in AIDS incidence was highest for PCP, at five cases per 1,000 every 6 months from 1994 to 1996 (P Å .004). The KS incidence rate declined at a rate of three cases per 1,000 every 6 months from 1994 to 1996 (P õ .001). Incidence of all other primary AIDS diagnoses combined decreased at a rate of 11 cases per 1,000 every 6 months (P õ .001) during the study period. Changes in other AIDS disease categories, such as infections due to Candida species, cytomegalovirus, and MAC, neurological disorders (progressive multifocal leukoencephalopathy and dementia), and wasting disease, are noted in figure 3. Declines in AIDS incidence were most marked for infections due to Candida species (two cases per 1,000 participants; P Å .010). However, the small numbers in each of these categories impairs meaningful analysis of individual diseases. The AIDS inci- There was a statistically significant decline in incidence of infections due to Candida species (P Å .010), wasting disease (P Å .006), and dementia (P Å .046) but not MAC infection (P Å .115), CMV infection (P Å .714), or herpes simplex virus infection (data not shown; P Å .284).
Results

From
suppression, as reflected by CD4
/ cell counts (P õ .001 overall; figure 4).
Despite a decrease in the overall incidence rate of primary AIDS diagnoses among Drug Treatment Program participants, there was no statistically significant difference in the proportion of PCP, KS, and other AIDS index diagnoses from 1994 to 1996 (P Å .082; figure 5). PCP accounted for 28% of all primary AIDS diagnoses in 1994 and 42% of those in 1996 (P Å .048). Fifteen percent of individuals who developed AIDS in 1994 had KS as their primary diagnosis, while 11% did in 1996 (P Å .442).
Finally, we completed a separate analysis, grouping AIDS index diagnoses as amenable or nonamenable to treatment. As shown in figure 6 , from 1995 to 1996 the incidence of primary AIDS in the amenable group decreased at a rate of 9 cases per in 1994 vs. 58% in 1996; P Å .062).
/ 9c5c$$de25
11-10-98 21:47:45 cida UC: CID decline in incidence of AIDS-defining illnesses observed in our study. In British Columbia, the change in death rate due to AIDS has been related to the availability of newer antiretroviral agents, especially lamivudine (3TC) [21, 22] . Continued monitoring of AIDS index disease incidence and survival rates will allow us to characterize fully the impact of more recent therapeutic advances on a populational basis. For example, the substantial reduction in the AIDS case rate in 1996 is unlikely due to the advent of protease inhibitors; therefore, the impact of antiretroviral regimens containing such agents cannot be assessed from the current data set.
Certainly, the decrease in AIDS-defining illnesses parallels changes in the availability of and strategy applied in using antiretroviral agents over the period of study. Since 1992, the therapeutic guidelines of the British Columbia Center for Excellence in HIV/AIDS for the use of antiretroviral therapy have recommended double combination therapy for individuals with a CD4
/ cell count of £0.350 1 10 9 /L. This recommendation was expanded in December 1995 to make double combination therapy available to everyone with a CD4
/ cell count of 
Discussion
Our data demonstrate that there was a substantial decrease in the incidence of AIDS-defining illnesses in the province of British Columbia, Canada, from 1994 to 1996 among HIVpositive patients prescribed antiretroviral agents. This decrease accelerated in 1995. A similar decrease was noted among AIDS-defining illnesses amenable and nonamenable to therapy. Furthermore, these results indicate that the spectrum of AIDSdefining illnesses, their incidence relative to one another among patients prescribed antiretroviral therapy, and the level of immunosuppression at which AIDS develops have not changed substantially, despite the overall decline in incidence of AIDSdefining illnesses. PCP and KS remain the most common AIDS index illnesses in HIV-infected patients prescribed antiretroviral therapy in the modern era.
The finding of a decline overall in the incidence of primary AIDS-defining illnesses confirms earlier work demonstrating a decline in AIDS-related death rates in British Columbia [21, However, it is not clear that such changes account for the / 9c5c$$de25
11-10-98 21:47:45 cida UC: CID owing to a variety of factors [6 -9, 26 -28] . Thus, the incidence of PCP as a primary AIDS diagnosis declined after the advent of prophylactic therapies in the late 1980s and constituted the first major shift in the pattern of AIDS-defining illnesses described [9, 29] . Yet, although the efficacy of prophylactic regimens has been well documented [30] , PCP remains the most frequent opportunistic infection present at AIDS diagnosis in developed countries [26, 29] . Our results indicate that PCP continues to be the predominant AIDS-defining illness in the modern era of antiretroviral therapy. Hence, prophylaxis for PCP remains of primary importance [31, 32] . Given increasing evidence that KS is related to infection with a sexually transmissible herpesvirus [33 -35] , change in incidence of KS as an AIDS-defining illness can be anticipated to parallel changes in the behaviors and demographics of HIVinfected individuals. Indeed, a substantial shift in the occurrence of KS has been reported widely, with a decreasing trend as a primary AIDS diagnosis and more frequent development at a later stage of HIV disease [34, 36, 37] . Previous data indicate a substantially stable incidence of KS as an AIDS index disease among Canadian HIV-positive patients since 1987 [28, 38] . Data from the present study suggest a decreasing prescribed antiretroviral therapy between 1 January 1994 and 31 Deincidence of KS but no change in its relative frequency among cember 1996, stratified by whether the condition was considered to be amenable () or nonamenable (᭺) to treatment. There was no AIDS-defining illnesses.
significant difference between the proportions of AIDS index diseases There was a reduction in incidence of all other index AIDSconsidered amenable to therapy in 1994 vs. 1996 (P Å .062).
defining illnesses, but the proportion of patients developing these illnesses as index AIDS-related diseases relative to other AIDS-defining illnesses did not change over the 3 years of study. Given the small numbers of index AIDS-defining illThus, particularly since 1995, double and subsequently triple combination drug therapy (especially with newer agents) has nesses, it is unclear to what extent the observed changes may be related to prophylaxis (e.g., for infection related to Toxoplasma been widely available for those patients participating in the Drug Treatment Program.
gondii [39] or MAC) or to the impact of newer antiretroviral strategies. The effect of prophylaxis in reducing the incidence There are several other reasons to implicate changes in antiretroviral therapy in the observed decline in AIDS-defining of infection with MAC has been shown in a recent study [23] . Indeed, there is a suggestion that early immunologic rebound illnesses. First, most prophylactic regimens for HIV-related opportunistic infections were introduced in the late 1980s [24, related to initiation of aggressive combination antiretroviral therapy may be incomplete [40] or may unmask subclinical 25] and did not change substantially over the 3-year period of our study. Second, most patients enrolled in the Drug Treatment disease [41] . For example, retinitis due to cytomegalovirus infection has been reported to occur in patients in the first Program are managed in accordance with the therapeutic guidelines of the British Columbia Center for Excellence, which months after the start of combination antiretroviral therapy, in association with CD4 / cell counts of ú100 1 10 9 /L [42]. include clear recommendations regarding use of prophylaxis, and thus most participants had uniform access to preventive Hence, while no significant change was observed in the incidence overall of these other AIDS-defining illnesses relative therapies throughout the study period. Finally, the dramatic decrease during the study period in AIDS-defining illnesses to PCP and KS, it remains uncertain that this will continue in the modern era of antiretroviral therapy. not amenable to treatment provides compelling evidence that improvements in antiretroviral therapy might explain our obserIn this context, it is noteworthy that there was no significant change in CD4
/ cell count at the time of AIDS diagnosis. vations. Most important, however, a recent similar cohort study demonstrated definitively the impact of more intensive combiFurthermore, the incidences of amenable and nonamenable AIDS-defining illnesses decreased at similar rates. This implies nation antiretroviral regimens on HIV-related mortality rates [23] .
The second important finding of this study is that a decline that the improvement in CD4 / cell count occurring as a result of aggressive antiretroviral treatment is sufficient to protect in incidence of AIDS-defining illnesses was not coincident with a change in the spectrum or proportion of AIDS-defining against all AIDS-defining illnesses. Caution is advised in the interpretation of these data, because illnesses observed. Since the beginning of the AIDS epidemic, the pattern of AIDS-defining diseases has been very mutable, of the nature of the study design [1] . neity of the population studied. However, this does not detract 
